Chronic myeloid leukaemia, chronic phase: the decisions you may face

Cancer page →Second-opinion finder →

3 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Early / localised

Newly diagnosed chronic phase

5 optionsCompare side by side →

Imatinib 400 mg daily, a second-generation inhibitor (dasatinib, nilotinib, bosutinib) chosen by comorbidity and treatment goal, or asciminib (ASC4FIRST); PCR at 3, 6 and 12 months against ELN milestones.

Guideline

NCCN Guidelines: Chronic Myeloid Leukemia

The options, in plain words

ImatinibApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)

The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.

DasatinibApprovedSmall-molecule kinase inhibitor (BCR::ABL1, SRC)

Dasatinib is a second-generation BCR::ABL1 pill that, combined with the immunotherapy blinatumomab, can put Ph-positive ALL into deep remission with no chemotherapy at all.

NilotinibApprovedSmall-molecule BCR-ABL1 TKI (second generation)

Nilotinib is a second-generation CML pill that produces deeper responses faster than imatinib, at the cost of cardiovascular and metabolic side effects.

BosutinibApprovedSmall-molecule BCR-ABL1/SRC TKI

Bosutinib is a CML pill with less cardiovascular and pleural toxicity than its rivals; its main side effect is diarrhoea.

AsciminibApprovedSmall-molecule allosteric ABL1 inhibitor (STAMP)

Asciminib is a BCR::ABL1 blocker that binds a different pocket from every other TKI, approved for all newly diagnosed chronic myeloid leukaemia in 2024 and now being tested in Ph-positive ALL.

Also referenced:Molecular response (MMR, MR4, treatment-free remission)

The evidence behind it

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Phase 3 NCT04971226405 peopleevidence 48
Tests Imatinib, Dasatinib, Nilotinib, Bosutinib, Asciminib
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
No headline result recorded yet.
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Phase 3 NCT05456191568 peopleevidence 49
Tests Nilotinib, Asciminib
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.
No headline result recorded yet.

The main trade-offs on record

Imatinib all recorded rates →

Take with a meal and a large glass of water.

Dasatinib all recorded rates →

Side effect	Any grade	Grade 3+
Pleural effusion · CML long-term data	28%	-

Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Nilotinib all recorded rates →

Take on an empty stomach (no food 2 hours before or 1 hour after): food raises exposure up to 82% and QT risk.
Known QT prolongation. Boxed warning for QT prolongation and sudden death: avoid QT-prolonging drugs; ECG at baseline, 7 days and after dose changes; correct potassium and magnesium.
Reduce dose in impairment per label.

Bosutinib all recorded rates →

Take with food.
200 mg daily in any hepatic impairment.

Asciminib all recorded rates →

Side effect	Any grade	Grade 3+
Thrombocytopenia	-	17%

Take on an empty stomach.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Questions to ask about this decision

Between Imatinib, Dasatinib, Nilotinib and the other options, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP and A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP), and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
Which side effects of Dasatinib or Asciminib are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Guidelines: Chronic Myeloid Leukemia), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (newly diagnosed chronic phase), which of the standard options do you recommend and why?
Why: Guideline options include: Imatinib 400 mg daily, a second-generation inhibitor (dasatinib, nilotinib, bosutinib) chosen by comorbidity and treatment goal, or asciminib (ASC4FIRST); PCR at 3, 6 and 12 months against ELN milestones.
Am I a candidate for Imatinib, Dasatinib, Nilotinib or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP and A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Resistance or intolerance

5 optionsCompare side by side →

Switch inhibitor guided by kinase domain mutation testing; ponatinib or asciminib for T315I; radotinib or olverembatinib where approved; allogeneic transplant after failure of two or more inhibitors.

Guideline

NCCN Guidelines: Chronic Myeloid Leukemia

The options, in plain words

PonatinibApprovedSmall-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I)

Ponatinib is the only BCR::ABL1 inhibitor that covers the T315I resistance mutation. In 2024 it became the preferred pill for newly diagnosed Ph-positive ALL.

AsciminibApprovedSmall-molecule allosteric ABL1 inhibitor (STAMP)

Asciminib is a BCR::ABL1 blocker that binds a different pocket from every other TKI, approved for all newly diagnosed chronic myeloid leukaemia in 2024 and now being tested in Ph-positive ALL.

OlverembatinibApprovedOral third-generation BCR-ABL tyrosine kinase inhibitor

Olverembatinib is Ascentage Pharma's third-generation BCR-ABL inhibitor, approved in China in 2021 for chronic myeloid leukaemia carrying the T315I mutation, and now in global phase 3 trials against the established drugs; it was the one China-only approval OnCo found missing from the headline list.

RadotinibPhase 3Oral kinase inhibitor

Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.

Allogeneic stem cell transplantationStandard of care

Allogeneic stem cell transplantation replaces a patient's blood system with a donor's after conditioning chemotherapy, so donor immune cells hunt down leukaemia left behind. It remains the only cure for adverse-risk acute myeloid leukaemia, high-risk acute lymphoblastic leukaemia and Richter transformation, at the price of graft-versus-host disease.

Curative for otherwise incurable leukaemia
Graft-versus-leukaemia is an antigen-agnostic immune therapy

The evidence behind it

Study of Olverembatinib (HQP1351) in Patients With CML-CP Phase 3 NCT06423911333 peopleevidence 48
Tests Olverembatinib
A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)
No headline result recorded yet.
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Phase 3 NCT03459534173 peopleevidence 46
Tests Radotinib
A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
No headline result recorded yet.
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia Phase 2 NCT0538458734 peopleevidence 28
Tests Asciminib
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)
No headline result recorded yet.

The main trade-offs on record

Ponatinib all recorded rates →

Side effect	Any grade	Grade 3+
Arterial occlusive events · CML long-term data at 45 mg; lower with response-based dose reduction	26%	-

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Asciminib all recorded rates →

Side effect	Any grade	Grade 3+
Thrombocytopenia	-	17%

Take on an empty stomach.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

Allogeneic stem cell transplantation

Treatment-related mortality 10-20%
Chronic GVHD
Relapse remains the main cause of failure

Questions to ask about this decision

Between Ponatinib, Asciminib, Olverembatinib and the other options, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in Study of Olverembatinib (HQP1351) in Patients With CML-CP and A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
Which side effects of Ponatinib or Asciminib are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Guidelines: Chronic Myeloid Leukemia), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (resistance or intolerance), which of the standard options do you recommend and why?
Why: Guideline options include: Switch inhibitor guided by kinase domain mutation testing; ponatinib or asciminib for T315I; radotinib or olverembatinib where approved; allogeneic transplant after failure of two or more inhibitors.
Am I a candidate for Ponatinib, Asciminib, Olverembatinib or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of Study of Olverembatinib (HQP1351) in Patients With CML-CP and A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Sustained deep molecular response

One path named

Attempt treatment-free remission after at least three to five years of therapy and two years of MR4 or better, with monthly PCR for six months; restart on loss of major molecular response.

Guideline

NCCN Guidelines: Chronic Myeloid Leukemia

The path, in plain words

Residual disease kinetics (BCR-ABL halving and ctDNA slopes)Established

The speed at which a molecular marker falls during treatment predicts outcome better than a single level: BCR-ABL halving time in chronic myeloid leukaemia and circulating tumour DNA slopes in solid tumours are now used to judge response within weeks.

Predicts outcome weeks into treatment
Standard in chronic myeloid leukaemia
Emerging early endpoint for trials

Also referenced:Minimal / molecular residual disease (MRD)Molecular response (MMR, MR4, treatment-free remission)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Residual disease kinetics (BCR-ABL halving and ctDNA slopes)

Depends on assay sensitivity and shedding
Cut-offs vary by disease and assay
Not yet standard in most solid tumours

Questions to ask about this decision

Is Residual disease kinetics (BCR-ABL halving and ctDNA slopes) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Guidelines: Chronic Myeloid Leukemia), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (sustained deep molecular response), which of the standard options do you recommend and why?
Why: Guideline options include: Attempt treatment-free remission after at least three to five years of therapy and two years of MR4 or better, with monthly PCR for six months; restart on loss of major molecular response.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.